Designing Novel Lipids that Redefine Delivery of Nucleic-Acid Therapeutics
AldexBIO’s lipids are reshaping LNPs and successful therapeutic delivery
Platform
Unique drug delivery platform that produces highly diverse novel lipids with high efficiency.
Novelty
Ability to design and synthesize billions of novel next-generation lipids.
Protection
Double-layer IP protection on all lipid structures, allowing freedom to operate.
Team
EU-based team with decades of experience in chemistry and drug development.
The AldexBIO Platform
Powerful platform features
Enables fast design and synthesis of novel lipids that are customizable for specific use cases.
Novel: New-generation lipids with unique features.
Tailored for purpose: Customized lipid design for specific use cases.
High throughput lipid optimization: Rapidly design, test, and customize lipids.
Freedom to operate: Drug development with no risk of infringement on existing IP.
The AldexBIO Platform
Protected by two layers of IP
Five international patent applications filed from 2020 till 2024, protecting the AldexBIO lipids and the proprietary AldexBIO technology.
The AldexBIO Platform
Designed for optimization
Designed to support data-driven optimization processes in drug development.
The AldexBIO Platform
Proven scalability
Proven manufacturing scalability, supporting any asset from research to commercial scale.
Toxicology and Safety
From hundreds of lipids on shelf, AldexBIO selected front-runner candidates by testing cellular toxicity with in vitro and in vitro throughput screens. In vivo investigations are ongoing, delivering encouraging results.
Toxicology and Safety
In vitro throughput studies identified multiple AldexBio lipids with low toxicity.
Toxicology and Safety
AldexBio lipids outperformed industry standard in in vitro viability assays with HepG2 cells.
Toxicology and Safety
In vivo, LNPs from AldexBio lipids showed tolerability comparable to industry standard.
‑All animals tolerated the formulations well.
‑No animal showed any clinical observation immediately post dose.
Lipids with low toxicity.
Promising tolerability.
Convincing in vitro toxicity results.
Transfection Efficacy
From hundreds of lipids on shelf, AldexBIO selected front-runner candidates by testing transfection efficacy with in vitro and in vitro throughput screens. In vivo investigations are ongoing, delivering encouraging results.
Transfection Efficacy
LNPs manufactured with AldexBio lipids performed superior in in vitro transfection studies compared to industry standards.
Transfection Efficacy
In an in vivo immunization model AldexBio lipids demonstrated superiority compared to an industry standard.
Transfection Efficacy
LNPs with AldexBio lipids display successful transfection in an early proof of principle study in mice.
Excellent in vitro transfection results.
Superior transfection in an in vivo immunization model.
Promising transfection in additional in vivo studies.
The AldexBIO Platform
Novel lipids with unique properties.
Double layer IP protection.
Application specific design.
Iterative optimization.
Scalable technology.
Low in vitro toxicity.
Well tolerated in vivo.
Excellent in vitro transfection.
Excellent in vivo transfection.
